If you take away one thing from this article, let it be this: the standard lipid panel is incomplete. It measures the cholesterol content of your lipoproteins, but it does not measure the number of atherogenic particles circulating in your blood. That particle count — measured by apolipoprotein B, or ApoB — is the single best predictor of cardiovascular risk. And it is almost never tested.
This is not a niche issue for researchers. It is a practical, everyday problem for AAS users who rely on blood work to manage their health. If your doctor is only ordering standard lipids, you are flying blind on cardiovascular risk.
Every "bad" lipoprotein particle in your blood — VLDL, IDL, LDL, and Lp(a) — contains exactly one ApoB molecule. That means measuring ApoB gives you a direct count of every atherogenic particle in circulation. It is the closest thing we have to a "cardiac body count."
🚚Imagine two delivery trucks carrying the same total load. One truck carries 100 small boxes. The other carries 10 large boxes. The total cargo weight is identical, but the number of vehicles on the road is very different. ApoB counts the vehicles. LDL cholesterol weighs the cargo. Cardiovascular risk is driven by the number of vehicles, not the cargo weight.
— The delivery truck analogy
This distinction matters enormously for AAS users. Androgenic compounds alter both thesize and the number of LDL particles. Some users develop many small, dense LDL particles — the most atherogenic kind — while their calculated LDL cholesterol appears only mildly elevated. Standard LDL would tell you "borderline risk." ApoB would tell you "this is dangerous."
Standard Lipid Panel vs. Complete Panel + ApoB
| Marker | Standard Panel | Complete Panel |
|---|---|---|
| Total Cholesterol | Yes | Yes |
| HDL | Yes | Yes |
| LDL (calculated) | Yes | Yes |
| LDL (direct) | No | Yes |
| Triglycerides | Yes | Yes |
| ApoB | No | Yes |
| Lp(a) | No | Recommended |
| Non-HDL cholesterol | Calculated | Calculated |
| Particle count | Unknown | Known via ApoB |
| Small dense LDL | Unknown | Inferred from ApoB |
Apolipoprotein B (ApoB)
LDL Cholesterol (Calculated)
HDL Cholesterol
Based on current evidence and expert consensus for individuals with elevated cardiovascular risk — which includes AAS users — here are the ApoB targets you should aim for:
Below 90
mg/dL (0.9 g/L)
Low cardiovascular risk. Continue current management. Recheck every 8-12 weeks on cycle.
90-109
mg/dL (0.9-1.1 g/L)
Acceptable for AAS users on cycle. Monitor with each panel. Consider adjunct therapy if trending upward.
110-129
mg/dL (1.1-1.3 g/L)
Add ezetimibe or low-dose statin. Increase omega-3 intake. Reduce dose or remove oral compounds.
130+
mg/dL (1.3+ g/L)
Medical consultation strongly recommended. Aggressive lipid management indicated. Consider ending cycle.
Cost and Convention
A standard lipid panel costs around $15-30. Adding ApoB costs another $20-40. Many insurance plans consider it "experimental" or not medically necessary for routine screening. Most doctors simply do not order it, because standard guidelines (ATP III, ESC) have only recently begun to emphasize ApoB as a primary target.
The result is a system where clinicians manage cardiovascular risk using a proxy (LDL) while the actual risk metric (ApoB) sits on the shelf. For the general population, this gap may be acceptable. For AAS users — who already have elevated cardiovascular risk — it is a dangerous blind spot.
LDL Alone Can Be Misleading
Consider a real example: A user on 500 mg testosterone per week has LDL at 150 mg/dL (borderline high) with HDL at 28 mg/dL (low). A standard assessment would say: moderate dyslipidemia. Nothing alarming.
But the same user's ApoB might be 130 mg/dL — which places them in the high-risk category. Their LDL number says "moderate concern" while their ApoB says "real danger." Without ApoB, this user walks away from their doctor's appointment reassured and under-informed. The LDL number is a guess. The ApoB is the truth.
Getting ApoB added to your panel is simpler than you might think. Here is exactly what to do.
Ask Your Doctor
Request "apolipoprotein B" added to your next lab requisition. Use the full name to avoid confusion with ApoA1 (a different marker).
Push Back If Needed
If your doctor refuses, explain you are using performance hormones and need comprehensive cardiovascular risk assessment, not routine screening.
Self-Order
Use a direct-to-consumer lab like LabCorp or Quest. The $20-40 cost is trivial compared to the value of knowing your true risk.
ApoB vs. LDL Discordance
In roughly 20% of individuals, ApoB and LDL give different risk signals. This is called discordance, and it is more common in insulin-resistant and hypertriglyceridemic individuals — two groups with significant overlap with AAS users.
When ApoB and LDL disagree, the evidence consistently shows that ApoB is the better predictor of outcomes. A landmark study in the Journal of the American College of Cardiology found that ApoB was superior to LDL in predicting cardiovascular events in every population studied. If you can only afford one advanced lipid test, make it ApoB.
Also Add: Non-HDL Cholesterol and Lp(a)
Non-HDL cholesterol (total minus HDL) is a reasonable proxy if ApoB is unavailable. It captures cholesterol from all atherogenic particles, not just LDL. It is not as accurate as ApoB, but it is better than calculated LDL alone.
Lipoprotein(a) or Lp(a) is a genetically determined risk factor that does not change significantly with lifestyle or most medications. Test it once in your life — if it is elevated, you need more aggressive lipid management regardless of your other numbers.